Aciclovir

DRUG9 trials

Sponsors

Friedrich Schiller Universitaet Jena, Beacon Therapeutics (USA) Inc., Fondazione Gimema Franco Mandelli Onlus, Region Uppsala, EMS

Conditions

Acute Herpes ZosterGENITAL HERPESHerpes ZosterPatients in the intensive care unit on ventilation with pneumonia and detection of herpes simplex virus type 1 (HSV-1) in bronchoalveolar lavage (BAL).Patients with relapsing-remitting multiple sclerosis with less than 10 years disease duration.Relapsing-remitting Multiple SclerosisVery High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL)Viral Pneumonia

Phase 2

Daratumumab in adults with Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL) Treated According to the ALL National Treatment Program (DARATALL-VHR)- GIMEMA ALL3024

RecruitingCTIS2024-511627-34-00

Fondazione Gimema Franco Mandelli OnlusVery High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL)

Start: 2024-10-17Target: 31Updated: 2025-12-23

The HIt HArd and hiT early in multiple sclerosis trial – HiHat trial

Not yet recruitingCTIS2024-519700-28-01

Region UppsalaPatients with relapsing-remitting multiple sclerosis with less than 10 years disease duration.

Target: 50Updated: 2025-10-22

Phase 3

Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes

CompletedNCT01281007

EMSGENITAL HERPES

Start: 2012-07-31End: 2015-03-31Updated: 2021-04-21

Efficacy of Oral Famciclovir Versus Aciclovir Treatment in Patients With Herpes Zoster

CompletedNCT01327144

EMSHerpes Zoster

Start: 2012-06-30End: 2017-07-31Updated: 2019-04-17

Effect of acyclovir therapy on the outcome of ventilated patients with lower respiratory tract infection and detection of herpes simplex virus in bronchoalveolar lavage

RecruitingCTIS2023-504322-19-00

Friedrich Schiller Universitaet JenaPatients in the intensive care unit on ventilation with pneumonia and detection of herpes simplex virus type 1 (HSV-1) in bronchoalveolar lavage (BAL).

Start: 2024-01-10Target: 710Updated: 2025-08-21

A Randomized, Controlled, Masked, Multi-center Study Evaluating the Efficacy, Safety, and Tolerability of Two Doses of AGTC-501 Compared to an Untreated Control Group in Male Participants with X-linked Retinitis Pigmentosa

WithdrawnCTIS2024-511181-36-00

Beacon Therapeutics (USA) Inc.X-linked retinitis pigmentosa (XLRP)

Target: 5Updated: 2024-09-17

Phase 4

PTH - Preemptive Treatment for Herpesviridae

CompletedNCT02152358

Assistance Publique Hopitaux De MarseilleViral Pneumonia

Start: 2014-02-05End: 2023-04-05Updated: 2023-04-06

Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA

CompletedNCT02205489

Genzyme, a Sanofi CompanyRelapsing-remitting Multiple Sclerosis

Start: 2014-10-31End: 2016-04-30Updated: 2016-06-09

Unknown Phase

Efficacy of Electroacupuncture for Acute Herpes Zoster-Associated Pain and Biomarker Evaluation

RecruitingNCT07515885

Dexiong HanAcute Herpes Zoster

Start: 2025-09-01End: 2028-12-31Target: 228Updated: 2026-04-07

Related Papers

Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia

Blood2024-11-05

Effect of acyclovir therapy on the outcome of mechanically ventilated patients with lower respiratory tract infection and detection of herpes simplex virus in bronchoalveolar lavage: protocol for a multicentre, randomised controlled trial (HerpMV)

BMJ Open2024-04-012 citations

Acyclovir for Mechanically Ventilated Patients With Herpes Simplex Virus Oropharyngeal Reactivation

JAMA Internal Medicine2019-12-1664 citations

Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).

2019-01-069 citations

Randomized clinical trial of famciclovir or acyclovir for the treatment of herpes zoster in adults.

2018-05-0714 citations

Evaluation of Comprehensive Alemtuzumab Infusion Guidance in Patients With Relapsing-Remitting Multiple Sclerosis: EMERALD Study Design (P7.283)

Neurology2015-04-061 citations